Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:KIN

Kindred Biosciences (KIN) Stock Price, News & Analysis

Kindred Biosciences logo

About Kindred Biosciences Stock (NASDAQ:KIN)

Key Stats

Today's Range
$9.24
$9.26
50-Day Range
$9.08
$9.25
52-Week Range
$3.46
$9.28
Volume
178,496 shs
Average Volume
840,890 shs
Market Capitalization
$420.52 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Kindred Biosciences, Inc. is a development-stage biopharmaceutical company, which focuses on saving and improving the lives of pets. The company was founded by Richard Chin and Denise M. Bevers on September 25, 2012 and is headquartered in Burlingame, CA.

Kindred Biosciences Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
17th Percentile Overall Score

KIN MarketRank™: 

Kindred Biosciences scored higher than 17% of companies evaluated by MarketBeat, and ranked 892nd out of 952 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Kindred Biosciences.

  • Earnings Growth

    Earnings for Kindred Biosciences are expected to grow in the coming year, from ($0.71) to ($0.02) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Kindred Biosciences is -8.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Kindred Biosciences is -8.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Kindred Biosciences has a P/B Ratio of 5.29. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for KIN.
  • Dividend Yield

    Kindred Biosciences does not currently pay a dividend.

  • Dividend Growth

    Kindred Biosciences does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for KIN.
  • Search Interest

    1 people have searched for KIN on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Kindred Biosciences insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    13.69% of the stock of Kindred Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    66.89% of the stock of Kindred Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Kindred Biosciences' insider trading history.
Receive KIN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kindred Biosciences and its competitors with MarketBeat's FREE daily newsletter.

KIN Stock News Headlines

[Urgent] Starlink Set For The Largest IPO In History?
He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000! And now, Elon could be set to do it for the third and final time… with what might be his biggest breakthrough yet. And for the first time ever, you have the rare chance to profit BEFORE the upcoming IPO.
Kindred Hospital East Greensboro
Japan's Sony terminates $10 bln Zee India merger
European Shares Edge Higher With ECB Meeting In The Spotlight
Earnings Optimism May Contribute To Continued Strength On Wall Street
See More Headlines

KIN Stock Analysis - Frequently Asked Questions

Kindred Biosciences, Inc. (NASDAQ:KIN) announced its earnings results on Thursday, August, 5th. The biopharmaceutical company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.16) by $0.04. The biopharmaceutical company had revenue of $3.54 million for the quarter, compared to analysts' expectations of $8.12 million. Kindred Biosciences had a negative net margin of 529.26% and a negative trailing twelve-month return on equity of 54.19%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Kindred Biosciences investors own include CorMedix (CRMD), Sorrento Therapeutics (SRNE), Micron Technology (MU), bluebird bio (BLUE), Novavax (NVAX), Bristol-Myers Squibb (BMY) and Meta Platforms (META).

Company Calendar

Last Earnings
8/05/2021
Today
11/21/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:KIN
Fax
N/A
Employees
63
Year Founded
2013

Profitability

Net Income
$-21,800,000.00
Net Margins
-529.26%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$42.16 million
Book Value
$1.75 per share

Miscellaneous

Free Float
N/A
Market Cap
$420.52 million
Optionable
Optionable
Beta
1.30

Social Links

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

This page (NASDAQ:KIN) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners